Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

Aditxt, Inc. (ADTX)

1.8400
-0.2400
(-11.54%)
At close: May 7 at 4:00:00 PM EDT
1.8600
+0.02
+(1.09%)
Pre-Market: 9:05:54 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
133.9850
133.9850
645.1760
933.7150
105.0340
Cost of Revenue
627.4740
627.4740
756.8360
766.7790
77.9790
Gross Profit
-493.4890
-493.4890
-111.6600
166.9360
27.0550
Operating Expense
27,370.2090
27,370.2090
25,950.7650
25,103.0960
27,461.9830
Operating Income
-27,863.6980
-27,863.6980
-26,062.4250
-24,936.1600
-27,434.9280
Net Non Operating Interest Income Expense
-7,362.1910
-7,362.1910
-6,379.7340
-2,228.7380
-1,935.4660
Other Income Expense
205.8310
205.8310
51.7120
-484.9780
-17,000.9700
Pretax Income
-35,020.0580
-35,020.0580
-32,390.4470
-27,649.8760
-46,371.3640
Tax Provision
0
0
0
0
0
Net Income Common Stockholders
-40,353.4970
-40,353.4970
-32,700.7100
-27,687.5530
-46,371.3640
Diluted NI Available to Com Stockholders
-40,353.4970
-40,353.4970
-32,700.7100
-27,687.5530
-46,371.3640
Basic EPS
-19.14k
--
-249.62k
-2.77M
-23.19M
Diluted EPS
-19.14k
--
-249.62k
-2.77M
-23.19M
Basic Average Shares
2.1080
--
0.1310
0.0100
0.0020
Diluted Average Shares
2.1080
--
0.1310
0.0100
0.0020
Total Operating Income as Reported
-27,863.6980
-27,863.6980
-26,062.4250
-25,480.0980
-41,934.9280
Total Expenses
27,997.6830
27,997.6830
26,707.6010
25,869.8750
27,539.9620
Net Income from Continuing & Discontinued Operation
-34,446.4860
-34,446.4860
-32,380.8390
-27,649.8760
-46,371.3640
Normalized Income
-34,860.9870
-34,860.9870
-32,380.8390
-27,105.9380
-29,370.3940
Interest Income
1.4540
1.4540
10.1660
57.3480
3.1010
Interest Expense
7,363.6450
7,363.6450
6,389.9000
2,286.0860
1,938.5670
Net Interest Income
-7,362.1910
-7,362.1910
-6,379.7340
-2,228.7380
-1,935.4660
EBIT
-27,656.4130
-27,656.4130
-26,000.5470
-25,363.7900
-44,432.7970
EBITDA
-27,039.1620
-27,039.1620
-25,457.9640
-24,827.8130
-43,956.5610
Reconciled Cost of Revenue
627.4740
627.4740
756.8360
766.7790
77.9790
Reconciled Depreciation
617.2510
617.2510
542.5830
535.9770
476.2360
Net Income from Continuing Operation Net Minority Interest
-34,446.4860
-34,446.4860
-32,380.8390
-27,649.8760
-46,371.3640
Total Unusual Items Excluding Goodwill
414.5010
414.5010
0
-543.9380
-17,000.9700
Total Unusual Items
414.5010
414.5010
0
-543.9380
-17,000.9700
Normalized EBITDA
-27,453.6630
-27,453.6630
-25,457.9640
-24,283.8750
-26,955.5910
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 6/30/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

WINT Windtree Therapeutics, Inc.
0.8702
-3.31%
 
HEPA Hepion Pharmaceuticals, Inc.
0.3900
+20.41%
 
GLMD Galmed Pharmaceuticals Ltd.
1.2900
-11.64%
 
OCEA Ocean Biomedical, Inc.
0.0150
+4.17%
 
PSTV Plus Therapeutics, Inc.
0.5636
+12.74%
 
ONCO Onconetix, Inc.
0.0693
-0.14%
 
GNPX Genprex, Inc.
0.2800
-4.24%
 
APVO Aptevo Therapeutics Inc.
0.3900
-4.88%
 
ZVSA ZyVersa Therapeutics, Inc.
0.6848
+24.24%
 
PHIO Phio Pharmaceuticals Corp.
2.0400
+18.60%